This Article Full Text Full Text (PDF) All Versions of this Article: 41/4/950    most recent 01.HYP.0000063361.70525.3Cv1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Taddei, S. Articles by Salvetti, A. Search for Related Content PubMed PubMed Citation Articles by Taddei, S. Articles by Salvetti, A. Related Collections Cardiovascular Pharmacology Clinical Studies Endothelium/vascular type/nitric oxide

(Hypertension. 2003;41:950.)
© 2003 American Heart Association, Inc.

Scientific Contributions

Calcium Antagonist Treatment by Lercanidipine Prevents Hyperpolarization in Essential Hypertension

Stefano Taddei; Agostino Virdis; Lorenzo Ghiadoni; Daniele Versari; Guido Salvetti; Armando Magagna; Antonio Salvetti

From the Department of Internal Medicine, University of Pisa, Pisa, Italy.

Correspondence to Stefano Taddei, MD, Department of Internal Medicine, University of Pisa, Via Roma, 67, 56100 Pisa, Italy. E-mail s.taddei{at}int.med.unipi.it

Essential hypertension is associated with impaired endothelium-dependent vasodilation caused by oxidative stress-induced nitric oxide (NO) breakdown and compensatory production of a hyperpolarizing factor. To test whether calcium antagonist treatment can restore NO availability and prevent hyperpolarization through antioxidant properties, in 15 healthy subjects and 15 patients with essential hypertension, we studied forearm blood flow (strain-gauge plethysmography) modifications induced by intrabrachial bradykinin (5, 15, 50 ng/100 mL per minute), an endothelium-dependent vasodilator, in basal conditions, during infusion of N^G-monomethyl-L-arginine (L-NMMA, 100 µg/100 mL per minute), an NO-synthase inhibitor, and ouabain (0.72 µg/100 mL per minute), an Na⁺-K⁺ ATPase inhibitor to prevent hyperpolarization. These infusions were repeated in the presence of the antioxidant vitamin C (8 mg/100 mL/min). The response to sodium nitroprusside was also evaluated. In controls, vasodilation to bradykinin was inhibited by L-NMMA and remained unchanged by ouabain or vitamin C. In hypertensive patients, vasodilation to bradykinin was blunted and resistant to L-NMMA but sensitive to ouabain. Vitamin C increased the response to bradykinin and restored the inhibiting effect of L-NMMA while preventing the effect of ouabain. In hypertensive patients, infusions were repeated after 3-month treatment with lercanidipine (10 to 20 mg daily). Lercanidipine decreased plasma lipoperoxides, isoprostanes, and malondialdehyde and increased plasma antioxidant capacity. Moreover, lercanidipine increased the vasodilation to bradykinin and restored the inhibiting effect of L-NMMA on bradykinin-induced vasodilation while preventing the effect of ouabain. Finally, vitamin C no longer exerted its facilitating activity. These results indicate that in essential hypertension, lercanidipine increases endothelium-dependent vasodilation by restoring NO availability and preventing hyperpolarization, an effect probably determined by antioxidant activity.

Key Words: hypertension, essential • endothelium • nitric oxide • endothelium-derived factors • free radicals • antioxidants • calcium antagonists

This article has been cited by other articles:

				E. Grossman Does Increased Oxidative Stress Cause Hypertension? Diabetes Care, February 1, 2008; 31(Supplement_2): S185 - S189. [Abstract] [Full Text] [PDF]

				J. Menne, J.-K. Park, R. Agrawal, C. Lindschau, J. T. Kielstein, T. Kirsch, A. Marx, D. Muller, F. H. Bahlmann, M. Meier, et al. Cellular and molecular mechanisms of tissue protection by lipophilic calcium channel blockers FASEB J, May 1, 2006; 20(7): 994 - 996. [Abstract] [Full Text] [PDF]

				B. Tomlinson, I. F.F. Benzie, S. Taddei, A. Virdis, L. Ghiadoni, D. Versari, G. Salvetti, A. Magagna, and A. Salvetti Antioxidant Effect of Lercanidipine * Response Hypertension, October 1, 2003; 42 (4): e10 - e11. [Full Text] [PDF]